-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p

HAUPPAUGE, N.Y., May 11, 2026 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (NASDAQ: AMPG, AMPGR, AMPGZ) today announced that it will release its financial results for the first quarter ended March 31, 2026, on Wednesday, May 13, 2026, after the market close. The Company will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Investor Earnings Call DetailsDate/Time: Wednesday, May 13th, 2026, at 5:00 PM ETDial-in Number: 1-833-630-0019 (domestic) or 1-412-317-1807 (international)Online Replay: Audio file and call transcript will be posted to AmpliTech’s news page when available.Investor questions may be submitted to investors@amplitechgroup.com prior to the call About AmpliTech Group, Inc. AmpliTech Group, Inc. (NASDAQ: AMPG, AMPGW) designs, develops, and manufactures advanced RF and microwave...

CONVENING NOTICE TO THE EXTRAORDINARY GENERAL MEETING 2026 OF IBA SA – WEDNESDAY JUNE 10, 2026, AT 11:00 A.M. – Dear Shareholder, We have the honor of convening you to the Extraordinary General Meeting (the “EGM“) of IBA to be held on Wednesday June 10, 2026 at 11:00 A.M., to deliberate on the attached agenda. The EGM will be held in person at the Company’s headquarters. There will also be an online webcast, accessible upon prior registration, but it will not be possible to vote online. This is a simple webcast. Shareholders are strongly encouraged to vote in advance of the EGM, within the legal deadlines, by proxy or via the remote voting form (both of which are provided herewith), in order to facilitate the counting of votes. Alternatively, shareholders are offered the possibility of voting via the platform http://www.abnamro.com/evoting...

Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals LOUISVILLE, Colo., May 11, 2026 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that additional real-world clinical and economic data related to Nodify Lung® testing will be shared at the American Thoracic Society (ATS) Annual Meeting, May 15 – 20, 2026 | Orlando, FL. The presentations further reinforce the accelerating adoption of Biodesix blood-based testing for earlier detection of lung cancer. “The presentations at ATS highlight the real-world clinical value and economic advantages of lung nodule management programs that use Nodify Lung® testing for risk stratification,” said Scott Hutton, CEO of Biodesix. “It is encouraging to see major academic medical centers and community...

MIAMI, FL, May 11, 2026 (GLOBE NEWSWIRE) — RenX Enterprises Corp. (NASDAQ: RENX) (“RenX” or the “Company”), a biomass recycling, logistics, and real estate company, today issued the following letter to shareholders: To Our Shareholders, This letter comes at a moment when we believe the case for what RenX is building is increasingly compelling. Recent geopolitical disruption has upended global agricultural input markets. Conflict-driven volatility has put pressure on key trade routes and pushed prices higher for fertilizer products such as urea, anhydrous ammonia, and phosphate, at exactly the moment Northern Hemisphere farmers prepare to plant. American producers are paying more, earning less, and questioning whether they will have enough of the inputs they need for upcoming planting seasons. The same forces driving up the cost...

Single-serve, full-flavored malt beverages are available in select markets now in resealable, recyclable, uniquely shaped, glow-in-the-dark containersLYTT® Electric Coolers™ Contains 15% ABVSingle-serve, full-flavored malt beverages are available in select markets now for drinkers 21+Introducing LYTT® Electric Coolers™Six flavors packaged in unique, patent pending lightbulb-shaped containers that are glow-in-the-dark, resealable, and widely recyclableBoston, May 11, 2026 (GLOBE NEWSWIRE) — The bright minds behind some of The Boston Beer Company’s biggest innovations today introduce LYTT® Electric Coolers™, the newest single-serve beverage to light up the growing ready-to-drink space. Packaged in unique, patent pending lightbulb-shaped containers that are glow-in-the-dark, resealable, and...

Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape  Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Access the segment here Company to also participate in Virtual Investor Closing Bell event on May 13 featuring Sanjeev Luther and Dr. Robert Pierce Register for the Closing Bell event here  CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Robert Pierce, Chief Scientific Officer of Ernexa.  As part of the segment, Dr. Pierce provides insight into...

Strengthens Leadership Team and Board with additional business development, finance and royalty management expertiseSAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors. “We are excited to welcome Chris, who will be fully dedicated to Anaptys, and Owen, both of whom deepen our team’s strong mix of expertise across finance, business development, royalty management and strategic transactions,” said Daniel Faga, president and chief executive officer. “We believe these strong additions will continue Anaptys’ focus on protecting and returning the value of our royalty assets...

Hangzhou, China, May 11, 2026 (GLOBE NEWSWIRE) — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China, through its subsidiaries in China, today announced that it has entered into a strategic cooperation agreement (the “Agreement”) with Shanghai Novabioplus Biotechnology Co., Ltd. (“Novabioplus”), a provider of biological reagent products and solutions on April 13, 2026. The two parties aim to jointly develop a “Data-Model-Application” trinity of next-generation intelligent medical models. The long-term initiative aims to integrate WORK Medical’s digital transformation of AI-driven healthcare with Novabioplus’ extensive protein data resources and application scenarios, unlocking the latent value of biological data assets. WORK Medical continues to deepen its...